Back to the main directory
EarningsReview / Equity
- Good start to the year, full-year targets confirmed by BNP Paribas Exane
- Surprisingly calm by BNP Paribas Exane
- 1Q25 Revenues: overall in line with strong Moncler DTC up 4% organic by BNP Paribas Exane
- FY results first take by BNP Paribas Exane
- Wavelength tight, guidance light? by BNP Paribas Exane
- Itaú BBA on Ambev: Our Thoughts on Heineken’s 1Q25 Figures by Itau
- Kitron (Buy, TP: NOK60.00) - Pathway to accelerated growth by DnB Markets
- Sinch (Buy, TP: SEK31.00) - FX affecting estimates by DnB Markets
- Nykode Therapeutics (No_rec, TP: NOK) - A compromise by DnB Markets
- VEF (Buy, TP: SEK2.50) - Executing on exits and buybacks by DnB Markets
- Nordea (Buy, TP: SEK155.00) - Resilient returns at a discount by DnB Markets
- Pandora - Cutting forecasts on tariff uncertainty by Danske Bank Equity Research
- FQ1’25 preview: HashiCorp closes early and IBM makes new segment disclosures by BNP Paribas Exane
- FQ1’25 preview: Reassuring survey results, but many moving parts in FY25 by BNP Paribas Exane
- Health is wealth by BNP Paribas Exane
- BNPP April Software Reseller Survey Results: SAP extract. by BNP Paribas Exane
- FQ3 preview: AI demand likely robust, with weaker core by BNP Paribas Exane
- Nordea Bank - No Rating: A tight ship in stormy seas by Nordea
- F3Q25 production first take - Copper ahead, headwinds at BMA by BNP Paribas Exane
- Q1-25 results: First Take by BNP Paribas Exane
- Q1 results - orders ahead, underlying P&L light, Robotics spin-off announced by BNP Paribas Exane
- Q1 on par with expectations by BNP Paribas Exane
- Q325 sales: small miss (flattered by US stocking) by BNP Paribas Exane
- First take 1Q25 sales by BNP Paribas Exane
- Q1'25 First Take: 3% sales beat; FY25 guidance confirmed despite lower GLVP assumption by BNP Paribas Exane
- 1Q (slight) beat; guidance unchanged reflecting risk of further Somatuline generics pressure by BNP Paribas Exane
- 1Q25 Revenues: 10.5% growth in line with BNPPE and consensus by BNP Paribas Exane
- Strong start to the year but a bumpy road ahead by BNP Paribas Exane
- 1Q25 preview. Positive on volumes, less so on margins by BNP Paribas Exane
- 2Q25p - another blow-out print, update/-grade of 28 targets the next stop by BNP Paribas Exane
- Nordic Semiconductor (Buy, TP: NOK174.00) - Near-term momentum likely strong by DnB Markets
- Corem (Hold, TP: SEK4.80) - Another round of divestments by DnB Markets
- Embla Medical (Buy, TP: DKK34.00) - All eyes on tariffs by DnB Markets
- Ericsson (Hold, TP: SEK84.00) - 2025 could be a tale of two halves by DnB Markets
- Flerie (Buy, TP: SEK57.00) - Entering tougher times with care by DnB Markets
- Wipro (WPRO IN) by HSBC
- April reseller survey results point to slowing IT spend; adjusting estimates and price targets by BNP Paribas Exane
- Sandvik - Hold: A downturn still on the cards by Nordea
- Powering up: Elia charges ahead after capital boost by BNP Paribas Exane
- Macroeconomic uncertainty exposes core growth challenges by BNP Paribas Exane
- Near-term resilience and long-term excellence by BNP Paribas Exane
- Autoliv - Hold: The tariff turmoil has yet to begin by Nordea
- FQ1 preview: Demand outlook weakening. Valuation attractive by BNP Paribas Exane
- Refining & Petchems: Pictures and profits by BNP Paribas Exane
- Autoliv - Flawless Q1 and confident outlook by Danske Bank Equity Research
- Challenging for longer by BNP Paribas Exane
- F3Q25 production first take - Aluminium chain in-line, issues at Cannington by BNP Paribas Exane
- FQ2 25 first take: good set of results and guidance upgrade by BNP Paribas Exane
- Q2’25 results: First take by BNP Paribas Exane
- Elisa (=, EUR 45) 4Q24 Results: Financials in line, but MSR weakness continues by BNP Paribas Exane